Sinoway Industrial Co., Ltd.

Valsartan Intermediate 6306-52-1 Valsartan Intermediate 6306-52-1

Valsartan Intermediate 6306-52-1
Related Products
  • NanoActive alpha lipoic acid (ALA) 1077-28-7

    1.Basic information of NanoActive alpha lipoic acidProduct Name: NanoActive alpha lipoic acid (ALA)Other Names: NanoActive THIOOCTIC ACIDAppearance: yellow, viscous and transparent liquidTest Method: ...

  • NanoActive Astaxanthin 472-61-7

    1.Basic information of NanoActive AstaxanthinProduct Name: NanoActive AstaxanthinOther Names: NanoActive AstaAppearance: reddish to dark red, viscous and transparent liquidTest Method: HPLCCAS NO.: 47...

  • NanoActive Curcumin 458-37-7

    1.Basic information of NanoActive CurcuminProduct Name: NanoActive CurcuminOther Names: NanoActive turmeric extractAppearance: yellow, viscous and transparent liquidTest Method: HPLCCAS NO.: 458-37-7S...

Basic Information of Valsartan Intermediate 6306-52-1

  • CAS No.of key intermediates: 936623-90-4
  • ASSAY(HPLC): C24H29N5O3 46.2%~49.2%; C24H29N1O5 43.5%~46.5%; Sodium 6.2%~8.2%
  • Grade Standard: Medicine Grade
  • Model Number: Top Grade
  • Purity: High Purity
  • Color: white
  • PH: 6.5-8.5
  • Water: 4.5%~7.0%
  • Heavy metals: ≤10ppm

Usage of Valsartan Intermediate 6306-52-1

Sartan, one of the representative valsartan, is an orally active and specific angiotensin II (AT1) receptor antagonist that selectively acts on AT1 receptor subtypes, blocking Disruption of angiotensin II binding to AT1 receptors, which specifically antagonize AT1 receptors by about 20,000-fold compared to AT2 receptors, inhibits vasoconstriction and aldosterone release, resulting in hypotensive effects. The synthetic drug does not act on angiotensin-converting enzyme (ACE), renin and other receptors and does not inhibit the ion channel associated with blood pressure and sodium balance; the synthetic drug has no inhibitory effect on angiotensin converting enzyme and does not affect in vivo Bradykinin levels, thus leading to fewer side effects of cough than angiotensin-converting enzyme inhibitors. That is, valsartan reduces elevated blood pressure without affecting heart rate. For most patients, a single oral dose of oral antihypertensive effect within 2 hours, 4 to 6 hours up to the peak, the antihypertensive effect is maintained to 24 hours after taking the medication, the treatment of 2 to 4 weeks after the maximum antihypertensive effect, and during long-term treatment Maintain efficacy. Combined with thiazide diuretics can further enhance the antihypertensive effect. Valsartan abrupt termination of treatment will not cause high blood pressure "rebound" or other side effects. And, valsartan does not affect the total cholesterol, triglycerides, blood glucose and uric acid levels in hypertensive patients.

COA of Valsartan Intermediate 6306-52-1

Valsartan Intermediate

MORE_DETAIL Valsartan Intermediate 6306-52-1

Basic Information of Valsartan Intermediate 6306-52-1

  • CAS No.of key intermediates: 936623-90-4
  • ASSAY(HPLC): C24H29N5O3 46.2%~49.2%; C24H29N1O5 43.5%~46.5%; Sodium 6.2%~8.2%
  • Grade Standard: Medicine Grade
  • Model Number: Top Grade
  • Purity: High Purity
  • Color: white
  • PH: 6.5-8.5
  • Water: 4.5%~7.0%
  • Heavy metals: ≤10ppm

Usage of Valsartan Intermediate 6306-52-1

Sartan, one of the representative valsartan, is an orally active and specific angiotensin II (AT1) receptor antagonist that selectively acts on AT1 receptor subtypes, blocking Disruption of angiotensin II binding to AT1 receptors, which specifically antagonize AT1 receptors by about 20,000-fold compared to AT2 receptors, inhibits vasoconstriction and aldosterone release, resulting in hypotensive effects. The synthetic drug does not act on angiotensin-converting enzyme (ACE), renin and other receptors and does not inhibit the ion channel associated with blood pressure and sodium balance; the synthetic drug has no inhibitory effect on angiotensin converting enzyme and does not affect in vivo Bradykinin levels, thus leading to fewer side effects of cough than angiotensin-converting enzyme inhibitors. That is, valsartan reduces elevated blood pressure without affecting heart rate. For most patients, a single oral dose of oral antihypertensive effect within 2 hours, 4 to 6 hours up to the peak, the antihypertensive effect is maintained to 24 hours after taking the medication, the treatment of 2 to 4 weeks after the maximum antihypertensive effect, and during long-term treatment Maintain efficacy. Combined with thiazide diuretics can further enhance the antihypertensive effect. Valsartan abrupt termination of treatment will not cause high blood pressure "rebound" or other side effects. And, valsartan does not affect the total cholesterol, triglycerides, blood glucose and uric acid levels in hypertensive patients.

COA of Valsartan Intermediate 6306-52-1

Valsartan Intermediate
Related Articles
Leave a Message Email Us

we will contact you within 24 hours.

  • TEL:+86-0592-5854962
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//